Overview

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Acute hepatitis C is a liver disease related to a virus: hepatitis C virus (HCV). The type of Hepatitis C Virus present in Egypt (genotype 4), has the reputation to respond poorly to treatment at the chronic hepatitis stage. Without treatment, 85% of patients with acute hepatitis C become chronically HCV infected which means that the virus stays present in the body. Pegylated Interferon is a new form of Interferon that stays in the body for longer time and allows the patient to take less injection per week. It has also proved to be more effective than standard Interferon in treatment of chronic hepatitis C.
Phase:
Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborator:
Hoffmann-La Roche
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a